[Mechanisms of immune suppression of systemic inflammation by the action of the narrowband ultraviolet B (311 nm) therapy in patients with psoriasis].
In patients with psoriasis, there is increased secretion of serum cytokine IL-22 of CD4 T helper 17/22 types and pro-inflammatory mediators (IL-6, TNF-alpha). Narrowband UVB therapy during 12 weeks significantly reduced the levels of IL-6, TNF-alpha IL-22 compared to the standard treatment. Patients who are resistant to narrow band UVB therapy, the use of erythmogenic strategy leads to increase of immunosuppressive effects on systemic inflammation than suberythmogenic one.